Dhansa Labs Announces First Quarter Financial Results and Updates Governance Policies
Dhansa Labs Limited, formerly known as Ambey Laboratories Limited, has released its Unaudited Financial Results for the first quarter of Fiscal Year 2026-27. The results cover both standalone and consolidated financials, which were reviewed by the company's Statutory Auditor. Furthermore, the Board of Directors approved several policies following an increase in paidup share capital beyond ₹25 Crore.The financial statements detail the company's performance for the quarter ended June 30, 2026, alongside audited figures from the previous year. These results were reviewed by the Audit Committee and subsequently approved by the Board of Directors on August 14, 2026.
Financial Highlights (Quarter Ended June 30, 2026)
The company reported key operational metrics across both its standalone and consolidated entities.Standalone Financials Snapshot:
| Particular | Quarter ended 30 June 2026 (Unaudited) | Year ended 31 March 2026 (Audited) |
|---|---|---|
| Revenue from operations | 3,056.29 lakhs | 14,153.72 lakhs |
| Other income | 0 | 151.30 lakhs |
| Total Income | 3,059.56 lakhs | 14,305.02 lakhs |
| Net Profit after tax | 72.59 lakhs | 57,326 lakhs |
Consolidated Financials Snapshot:
| Particular | Quarter ended 30 June 2026 (Unaudited) | Year ended 31 March 2026 (Audited) |
|---|---|---|
| Revenue from operations | 3,056.29 lakhs | 14,153.72 lakhs |
| Other income | 327 lakhs | 130.96 lakhs |
| Total Income | 3,059.56 lakhs | 14,284.68 lakhs |
| Net Profit after tax | 72.59 lakhs | 552.26 lakhs |
Capital Structure and Fund Utilization
The company provided detailed insights into the utilization of funds raised against its convertible equity warrants. During the year ended March 31, 2026, Dhansa Labs allotted 1,08,69,565 convertible equity warrants on a preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs.Against these warrants, the company received an aggregate amount of Rs. 2,161.53 lakhs up to June 30, 2026, towards warrant subscription money/part consideration. During the quarter ended June 30, 2026, 19,56,521 warrants were converted into equity shares.
The company confirmed that the funds received have been fully utilized against the objectives of the issue. The allocation details are summarized below:
| Object of Issue | Total Issue Size | Amount Received till June 30, 2026 | Amount Utilized till June 30, 2026 | Unutilized Amount as on June 30, 2026 |
|---|---|---|---|---|
| General corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances. | 4,999.99 lakhs | 2,161.53 lakhs | 2,161.53 lakhs | - |
Governance and Administrative Updates
The Board meeting confirmed the adoption of several governance policies in response to the increase in paidup share capital. These policies include: Policy For Determination of Material Subsidiary, Preservation of Documents & Archival Policy, Policy For Determination of Materiality of Events or Information, Remuneration Policy, and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.Furthermore, a change was noted regarding the company secretary's compliance details. Himanshu Kukreja is the Company Secretary and Compliance Officer, with his email ID changing from cs@ambeylab.com to cs@dhansagroup.com.
DHANSA Stock Price Movement
Shares of Dhansa Labs Limited are edging higher to ₹21.5 as of 1:17 PM today, surging following a gain of 4.88%. The stock’s performance in live trading comes alongside a traded volume of 2,000 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.